Eton Pharmaceuticals
About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc., a privately held company, is focused on the development and commercialization of innovative sterile injectable product candidates utilizing the FDA 505(b)(2) regulatory pathway.79 articles with Eton Pharmaceuticals
-
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
5/12/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the first quarter ended March 31, 2022.
-
Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
5/3/2022
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12, 2022.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
4/11/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced the appointment of James Gruber as Chief Financial Officer, effective immediately.
-
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
4/11/2022
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its cysteine hydrochloride abbreviated new drug application (ANDA), a bioequivalent generic of Exela Pharma Sciences’ Elcys™
-
Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results
3/16/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the fourth quarter ended December 31, 2021.
-
Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)
3/14/2022
Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine hydrochloride) injection.
-
Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
3/8/2022
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it will report fourth quarter 2021 financial results on Wednesday, March 16, 2022.
-
January has been a largely quiet month for PDUFA dates on the U.S. Food and Drug Administration (FDA)’s calendar. There were two dates for the entire month, and one of those has been moved back to April. Here’s a look.
-
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
12/20/2021
Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets.
-
Iterum Therapeutics will head back into the clinic to meet regulatory requirements to refile a New Drug Application for oral sulopenem.
-
Eton Pharmaceuticals Reports Third Quarter 2021 Financial Results
11/15/2021
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the third quarter ended September 30, 2021.
-
Eton Pharmaceuticals Announces Co-Promotion Agreement with Tolmar Pharmaceuticals for ALKINDI SPRINKLE®- Tolmar’s 62-person sales force will co-promote ALKINDI SPRINKLE® to pediatric endocrinologists -
11/15/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON) today announced that it has entered into a multi-year agreement with Tolmar Pharmaceuticals, Inc. to co-promote ALKINDI SPRINKLE®.
-
Eton Pharmaceuticals and Azurity Pharmaceuticals, Inc. Announce FDA Approval of EPRONTIA™ (topiramate) Oral SolutionThe first and only FDA-approved ready-to-use liquid topiramate
11/8/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON) and Azurity Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EPRONTIA™ (topiramate) oral solution, 25mg/mL.
-
Eton Pharmaceuticals to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
11/3/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2021 financial and operating results on Monday, November 15, 2021.
-
Eton Pharmaceuticals Announces Acquisition of Approved Orphan Drug Product Carglumic Acid-Product is the first generic alternative to one of the highest priced pharmaceutical products in the world
10/28/2021
Eton Pharmaceuticals, Inc today announced that it has acquired U.S. marketing rights to carglumic acid tablets.
-
The U.S. FDA has a busy period at the end of October heading into the first week of November.
-
Eton Pharmaceuticals Reports Second Quarter Financial Results
8/16/2021
Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the second quarter ended June 30, 2021.
-
Eton Pharmaceuticals to Report Second Quarter 2021 Financial Results on Monday, August 16, 2021
8/3/2021
Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that it will report second quarter 2021 financial and operating results on Monday, August 16, 2021.
-
The U.S. FDA is starting off August with a mix of PDUFA dates for acne products, seizure medications and a new manufacturing process for a non-opioid pain killer. Here’s a look.